Difluprednate
Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a609025 |
License data |
|
Routes of administration | topical dermatologic |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.041.636 |
Chemical and physical data | |
Formula | C27H34F2O7 |
Molar mass | 508.551 g·mol−1 |
|
Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Alcon under the tradename Durezol.
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2][3]
gollark: Correction: 300MB presently.
gollark: It uses an entire 400MB of RAM and needs a database and such.
gollark: I personally use Gitea, but it is possibly somewhat big and overkill.
gollark: Actually, I don't.
gollark: I see.
References
- "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
- ClinicalTrials.gov
- {Sheppard J, Toyos M, Kempen, J, Kaur P, Foster C "Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Opthalmol Vis Sci 2014 May 6;55(5):2993-3002. doi:10.1167/iovs.13-12660.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.